GlassScriptPhysician profile
Halyn Cade Mccarty
NPI 1346914629
$4,910.17
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,871 · 2023: $1,655 · 2024: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.73 | 2022-2024 | |
| Lilly USA, LLC | $419.96 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $410.57 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.12 | 2022-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $269.44 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $236.81 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.80 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.09 | 2022-2024 | Trintellix |
| Amgen INC. | $211.54 | 2022-2024 | Repatha, Prolia, Evenity |
| Dexcom, INC. | $199.44 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $159.45 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $154.58 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $116.09 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $108.42 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $98.44 | 2023 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.82 | 2022-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $75.16 | 2022 | |
| Tris Pharma INC | $71.38 | 2023-2024 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $67.73 | 2022-2023 | |
| Astellas Pharma US INC | $59.05 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $57.32 | 2024 | Auvelity, Sunosi |
| Esperion Therapeutics, INC. | $53.78 | 2022-2023 | Nexletol |
| Lundbeck LLC | $45.65 | 2022 | |
| Shield Therapeutics INC | $42.67 | 2024 | |
| Daiichi Sankyo INC. | $39.79 | 2022 | |
| Sunovion Pharmaceuticals INC. | $39.29 | 2022 | |
| Abbott Laboratories | $36.85 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $27.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.91 | 2022 | |
| Insulet Corporation | $22.28 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.25 | 2022 | |
| Mylan Specialty L.P. | $19.51 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halyn Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.